Join ResMed at ATS 2017

WASHINGTON – May 19, 2017 – ResMed will present new research into the treatment of chronic obstructive pulmonary disease (COPD) and central sleep apnea (CSA) at the 2017 American Thoracic Society International Conference (ATS) which starts today.

ATS attracts more than 15,000 respiratory medicine practitioners, scientists, clinical researchers, and related health care professionals. According to its organizers it is the longest running, large-scale conference in the world offering research in pulmonary, critical care, and sleep medicine.

This year's conference will offer many their first look at the ResMed AirTouch™ F20 full face mask with UltraSoft memory foam cushion, a breakthrough in the treatment of sleep apnea, and ResMed AirMini™, the world's smallest continuous positive airway pressure device.

ResMed innovation will be in evidence in a number of conference sessions including:

- A2 - Home Non-invasive Ventilation with Oxygen After COPD Exacerbation: A Randomized Clinical Trial
  - Sunday, May 21
  - 9:15 a.m. – 11:15 a.m.
  - Room 207 A-B (South Building, Level 2), Walter E. Washington Convention Center
- A2928 - Trajectories of Central Sleep Apnea During Continuous Positive Airway Pressure and Association with Therapy Termination: A Big Data Analysis
  - Monday, May 22
  - 9:15 a.m. – 11:15 a.m.
  - Room 152 A-B (Middle Building, Street Level), Walter E. Washington Convention Center

Dr. Adam Benjafield, ResMed's vice president of medical affairs, will present new clinical evidence on adaptive servo-ventilation (ASV) for CSA and non-invasive ventilation (NIV) for COPD at the company's stand at booth 436 in the exhibit hall at the following times.

- ASV for Sleep Apnea – New and Big Data
  - Sunday, May 21 at 12.30pm
  - Monday, May 22 at 1.30pm
  - Tuesday, May 23 at 12.00pm
- NIV therapy for COPD – Latest Evidence
  - Sunday, May 21 at 1.30pm
  - Monday, May 22 at 12.00pm
  - Tuesday, May 23 at 1.30pm

About ResMed

ResMed changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. ResMed.com | Facebook | Twitter | LinkedIn

# # #
